Abstract
F1 (SJL/J×C57BL/6) mice with MOG35-55-induced EAE recover from disease when treated with Ig-MOG carrying MOG35-55 peptide. However, Ig-PLP1, carrying PLP139-151, induced reduction of anti-MOG antibodies and exacerbated EAE. Herein, we show that Ig-PLP1 specifically reduces the frequency of B cells producing protective IgG2a/b anti-MOG antibodies. Surprisingly, these cells were marginal zone (MZ), rather than follicular (FO) or newly formed (NF), B cells and transfer of MZ B cells into sick mice nullified disease exacerbation by Ig-PLP1 in a complement dependent manner. These findings reveal a potential self-limiting regulatory mechanism involving auto-antibodies in MOG EAE.
Keywords:
Anti-MOG antibodies; Autoimmunity; B cells; EAE; T cell tolerance.
© 2013.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies / metabolism
-
B-Lymphocytes / immunology
-
B-Lymphocytes / metabolism
-
Cytokines / metabolism
-
Disease Models, Animal
-
Encephalomyelitis, Autoimmune, Experimental / chemically induced
-
Encephalomyelitis, Autoimmune, Experimental / immunology*
-
Encephalomyelitis, Autoimmune, Experimental / therapy*
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Flow Cytometry
-
Immune Tolerance / physiology*
-
Lymphocyte Activation / immunology
-
Mice
-
Mice, Inbred C57BL
-
Myelin-Oligodendrocyte Glycoprotein / adverse effects
-
Peptide Fragments / adverse effects
-
Statistics, Nonparametric
-
T-Lymphocytes / immunology*
Substances
-
Antibodies
-
Cytokines
-
Myelin-Oligodendrocyte Glycoprotein
-
Peptide Fragments
-
myelin oligodendrocyte glycoprotein (35-55)